Ahmad Ryad Hamdan

Mr. Ahmad Ryad Hamdan

College of Medicine, Qatar University, Doha, Ad Dawḩah, Qatar
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
AAAmeer Awashra
Ameer Awashra
MAMohammed AbuBaha
Mohammed AbuBaha
AEAhmed Emara
Ahmed Emara
Ahmad Ryad HamdanAhmad Ryad Hamdan
Ahmad Ryad Hamdan
AZAnwar K Zahran
Anwar K Zahran
ASAbdalhakim R. M. Shubietah
Abdalhakim R. M. Shubietah

2 March 2025 in Antibiotics
Verified
Journal Article
Open access
AAAbu-El-Ruz Abu-El-Ruz
Abu-El-Ruz Abu-El-Ruz
MHMohannad Natheef Abu Haweeleh
Mohannad Natheef Abu Haweeleh
Ahmad Ryad HamdanAhmad Ryad Hamdan
Ahmad Ryad Hamdan
HRHumam Rajha
Humam Rajha
JSJood Mudar Sarah
Jood Mudar Sarah
SZSusu Zughaier
Susu Zughaier
Background/Objectives: Artificial intelligence has made significant strides in healthcare, contributing to diagnosing, treating, monitoring, preventing, and testing various diseases. Despite its broad adoption, clinical consensus on AI’s role in infection control remains uncertain. This scoping review aims to understand the characteristics of AI applications in bacterial infection control. Results: This review examines the characteristics of AI applications in bacterial infection control, analyzing 54 eligible studies across 5 thematic scopes. The search from 3 databases yielded a total of 1165 articles, only 54 articles met the eligibility criteria and were extracted and analyzed. Five thematic scopes were synthesized from the extracted data; countries, aim, type of AI, advantages, and limitations of AI applications in bacterial infection prevention and control. The majority of articles were reported from high-income countries, mainly by the USA. The most common aims are pathogen identification and infection risk assessment. The most common AI used in infection control is machine learning. The commonest reported advantage is predictive modeling and risk assessment, and the commonest disadvantage is generalizability of the models. Methods: This scoping review was developed according to Arksey and O’Malley frameworks. A comprehensive search across PubMed, Embase, and Web of Science was conducted using broad search terms, with no restrictions. Publications focusing on AI in infection control and prevention were included. Citations were managed via EndNote, with initial title and abstract screening by two authors. Data underwent comprehensive narrative mapping and categorization, followed by the construction of thematic scopes. Conclusions: Artificial intelligence applications in infection control need to be strengthened for low-income countries. More efforts should be dedicated to investing in models that have proven their effectiveness in infection control, to maximize their utilization and tackle challenges.

14 December 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
Ahmad Ryad HamdanAhmad Ryad Hamdan
Ahmad Ryad Hamdan
MHMohannad Natheef Abu Haweeleh
Mohannad Natheef Abu Haweeleh
LALeena Al-Qassem
Leena Al-Qassem
AKAmira Kashkoul
Amira Kashkoul
Izzaldin AlremawiIzzaldin Alremawi
Izzaldin Alremawi
SZSusu Zughaier
Susu Zughaier
Background and Objectives: Diabetes is linked to a higher risk of urinary tract infections (UTIs) in women, often leading to recurrent antibiotic treatments. Frequent antibiotic use for UTIs can contribute to antimicrobial resistance (AMR), a critical public health threat that increases treatment failure. This study investigated the prevalence of AMR and its associated factors among women with UTIs, comparing those with and without diabetes. Results: The study population had a mean age of 52 years (SD = 23) for the women without diabetes and 68 years (SD = 14) for those with diabetes. Resistance was highest for cefazolin and levofloxacin in the Access and Watch antibiotic groups, while ciprofloxacin was the most frequently prescribed antibiotic. AMR prevalence was 35.7% among the women with diabetes and 21.3% among those without. After adjustment, AMR was significantly associated with both uncomplicated diabetes (OR 1.14, 95% CI 1.08–1.21) and complicated diabetes (OR 1.54, 95% CI 1.45–1.64), as well as with higher numbers of prescribed antibiotics (OR 277.39, 95% CI 253.79–303.17). Methods: Using a cross-sectional cohort from the Physionet database, we analyzed data on 116,902 female participants treated for UTIs, including their antibiotic exposure, diabetes status, comorbidities, and hospital admission details. Antimicrobials were classified per the WHO’s AWaRe criteria. The primary outcome was AMR identified in urine cultures, and the association with diabetes status was evaluated using multivariable logistic regression. Conclusions: Our findings highlight the need for focused antimicrobial stewardship in women with diabetes to reduce the AMR rates in this vulnerable group.

27 October 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
MHMohannad Natheef Abu Haweeleh
Mohannad Natheef Abu Haweeleh
Ahmad Ryad HamdanAhmad Ryad Hamdan
Ahmad Ryad Hamdan
JAJawaher Al-Essa
Jawaher Al-Essa
SAShaikha Aljaal
Shaikha Aljaal
NSNasser Al Saad
Nasser Al Saad
Mohamed ElrayessMohamed Elrayess
Mohamed Elrayess
The ongoing challenge of doping in sports has triggered the adoption of advanced scientific strategies for the detection and prevention of doping abuse. This review examines the potential of integrating metabolomics aided by artificial intelligence (AI) and machine learning (ML) for profiling small-molecule metabolites across biological systems to advance anti-doping efforts. While traditional targeted detection methods serve a primarily forensic role—providing legally defensible evidence by directly identifying prohibited substances—metabolomics offers complementary insights by revealing both exogenous compounds and endogenous physiological alterations that may persist beyond direct drug detection windows, rather than serving as an alternative to routine forensic testing. High-throughput platforms such as UHPLC-HRMS and NMR, coupled with targeted and untargeted metabolomic workflows, can provide comprehensive datasets that help discriminate between doped and clean athlete profiles. However, the complexity and dimensionality of these datasets necessitate sophisticated computational tools. ML algorithms, including supervised models like XGBoost and multi-layer perceptrons, and unsupervised methods such as clustering and dimensionality reduction, enable robust pattern recognition, classification, and anomaly detection. These approaches enhance both the sensitivity and specificity of diagnostic screening and optimize resource allocation. Case studies illustrate the value of integrating metabolomics and ML—for example, detecting recombinant human erythropoietin (r-HuEPO) use via indirect blood markers and uncovering testosterone and corticosteroid abuse with extended detection windows. Future progress will rely on interdisciplinary collaboration, open-access data infrastructure, and continuous methodological innovation to fully realize the complementary role of these technologies in supporting fair play and athlete well-being.

21 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MEMohamed Ragab Elhadary
Mohamed Ragab Elhadary
BEBasel Elsayed
Basel Elsayed
AEAmgad Mohamed Elshoeibi
Amgad Mohamed Elshoeibi
OKOmar Karen
Omar Karen
IEIbrahim Elmakaty
Ibrahim Elmakaty
MMMohammed Imad Malki
Mohammed Imad Malki
Background/Objective: This study aimed to determine the clinicopathological findings and prognostic value of chemokine receptor 7 (CCR7) expression in patients with breast cancer (BC). Methods: Up to the 25th of March 2025, a search was conducted using five databases: PubMed, Embase, Scopus, Medline, and Web of Science. The methodological standards for the epidemiological research scale were used to assess the quality of the included articles, and Stata software (Stata 19) was used to synthesize the meta-analysis. Results: We considered 12 of 853 studies that included 3119 patients with BC. High CCR7 expression was not associated with age (odds ratio [OR] 0.82, 95% confidence interval [CI] 0.66–1.03); clinicopathological findings, including tumor size (OR 1.062, 95% CI 0.630–1.791); clinical stage (OR 1.753, 95% CI 0.231–13.304); nodal metastasis (OR 1.252, 95% CI 0.571–2.741); or histological differentiation (OR 1.167, 95% CI 0.939–1.450). CCR7 expression did not affect overall survival (hazard ratio 0.996, 95% CI 0.659–1.505). Conclusions: Our quantitative analysis did not reveal an association between CCR7 expression and poor clinicopathological or prognostic features in BC patients. Because of the high heterogeneity and potential publication bias, large high-quality studies are required to further confirm these findings.

14 March 2024 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
OMOmran A. H. Musa
Omran A. H. Musa
ASAsma Syed
Asma Syed
MKMalkan A. Khatib
Malkan A. Khatib
Ahmad Ryad HamdanAhmad Ryad Hamdan
Ahmad Ryad Hamdan
AAAmrou Hub Allah
Amrou Hub Allah
SDSuhail A. Doi
Suhail A. Doi